Providing evidence-based digital therapies to improve treatment outcomes

Improving the lives of people suffering from mental illness and substance use disorders

Developing improved pharmaceuticals based on innovative drug delivery technologies

What we do



Commercializing and developing pharmaceuticals addressing large unmet needs

Digital Therapeutics

Digital Therapeutics

Product portfolio of scientifically proven digital therapies

Mental illness & substance use disorders

Mental illness & substance use disorders

Focusing on areas of great human suffering with wider societal implications

We Care

Shedding light on lives affected by addiction and the road to recovery

Our mission for our blog platform on which we share the stories and insights from individuals coping with addiction, recovery and mental health.

Key News

FEBRUARY 10, 2021
modia™ will be tested in patients in collaboration with and Magellan Rx Management

FEBRUARY 4, 2021
Great interest among institutional investors when issuing a corporate bond

FEBRUARY 1, 2021
Orexo contemplates issue of senior unsecured callable floating rate bonds 

Our history

Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.

Orexo Social

4 March 2021

We’re delighted to have been awarded an #EmployeeEngagement Best Practice #Award by @DecisionWise. Our employees ar…

3 March 2021

Friendly Reminder - Tomorrow on March 4th, Nikolaj Sørensen, CEO, will give a company update @redeye Investor Forum…

25 February 2021

Bob DeLuca, president of #orexo US, met @PsychTimes virtually and talked about modia™ our new and upcoming digtial…

Financial Snapshot

Group net revenues

663.6 MSEK



19.0 MSEK


US Pharma segment EBIT

331.2 MSEK


Cash position

505.3 MSEK

Q4 2020

1 Last Twelve Months, Q120-Q420, for more information about financial development Link